Biocon expects double-digit biosimilars growth; targets mid-20% margins
Biocon told CNBC-TV18 it expects double-digit revenue growth in its biosimilars business to continue. The company targets margins in the mid-20% range and expects improvement further.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.